Sector News

Sequana announces results from study of direct sodium removal

November 19, 2022
Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0.

Data from ten evaluable diuretic-resistant heart failure patients, with persistent congestion, who also completed a 16-week follow-up period after intensive DSR therapy, confirmed previously reported interim data demonstrating long-lasting clinical benefits.

At baseline, the patients with persistent congestion due to heart failure were on high dose loop diuretics and had high disease severity. All ten individuals safely, effectively and rapidly eliminated persistent congestion and achieved euvolemia within one week of commencing intensive DSR therapy, resulting in a mean weight loss of 7kg.

Furthermore, during the intensive DSR period, the diuretic response of the kidney was near-normalised, with excretion of sodium increasing more than 160% compared to the baseline. In addition, there was a considerable improvement in cardio-renal health.

Dr Jeffrey Testani, associate professor at Yale University and heart failure scientific advisor to Sequana Medical, explained: “Congestion is a key driver of heart failure and remains the leading cause of morbidity and hospitalisation in this large and growing patient population. Diuretic-resistance is widespread and the usual therapeutic approach is just adding more diuretics, further worsening the underlying issues.

He added: “There are no therapies that seek to correct the cardio-renal pathophysiology causing the diuretic-resistance.”

Dr Oliver Gödje, chief medical officer at Sequana Medical, added: “These results are very positive and reinforce our view that DSR is a potential disease-modifying heart failure therapy. We are excited to have the first patient dosed with DSR 2.0 and we are confident that this second-generation product will deliver important therapeutic and safety benefits.”

To evaluate the safety, tolerability and efficacy of the company’s second-generation DSR product – DSR 2.0 – a phase 1 study has been initiated in Canada with up to ten patients on peritoneal dialysis receiving a single treatment. Meanwhile, a further phase 1 study is due to take place in Mexico, followed by a randomised phase 1/2a study in the US during 2023.

By John Pinching


comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach